Arrayit Corp (OTCMKTS:ARYC) Launches Major Proteomics And Genomics Products
June 30, 2015 Jessica Tatom
Arrayit Corp (OTCMKTS:ARYC), a market leader in molecular diagnostic and life sciences, is proud to announce the launch of new proteomics and genomics products in the market. As per the reports, the global market for these products accounts over a billion; hence, Arrayit doesn’t want to leave any stone unturned to cash in this opportunity.
The new products and services will be announced in its image-rich, full color 2015/16 catalogue.
Insights On The Matter:
Some of the leading products that Arrayit Corp has launched include Arrayit High-Seq genomic labeling kits, InnoScan 910 and 1100 microarray scanners, HuProt v2.0 19K human proteome microarrays, etc. Apart from this, the company has also come up with TissueMax personal tissue microarrayers and series 3 glass consumables. All of these products have been features in company’s new catalogue. The prime objective of floating these products in the market is to improve the overall condition of agriculture, healthcare and food safety.
Arrayit Corp has decided to increase its proprietary microarray platform to elevate the analysis of human proteome and genome. These two are the blueprints of the body and impart various features of all living organisms. With the help of extensive proteomic and genomic information, doctors can easily take care of pre-symptomatic diagnostic tests, a personalized healthcare paradigm and safer medicines. The information makes it easy for the health experts to recommend optimal treatments to patients based on the unique information derived from their proteins and genes.
Newly announced products of Arrayit Corp are available across the globe through direct sales channels and a well-formed network of over 60 international distributors. The senior management of Arrayit is pleased to make this announcement and hopes that the market will respond in a positive way. Rene Schena, CEO, Arrayit Corp, states that the company has made a huge investment in proteomics and genomics products, which will surely lead to higher revenues in the near future.
